Cetuximab induces eme1-mediated DNA repair: a novel mechanism for cetuximab resistance.

Challenges to targeting epidermal growth factor receptor in glioblastoma: escape mechanisms and combinatorial treatment strategies. Neuro Oncol (2014) 0.85

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med (2004) 30.26

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med (2009) 24.75

The DNA damage response: making it safe to play with knives. Mol Cell (2010) 16.13

Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol (1995) 9.03

Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res (2008) 6.91

DNA repair pathways as targets for cancer therapy. Nat Rev Cancer (2008) 6.69

Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol (2006) 6.38

Interfaces between the detection, signaling, and repair of DNA damage. Science (2002) 5.33

Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell (2005) 4.73

DNA damage-induced cell death by apoptosis. Trends Mol Med (2006) 4.67

Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene (2008) 4.13

PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res (2008) 3.98

Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell (2005) 3.67

Structural and functional relationships of the XPF/MUS81 family of proteins. Annu Rev Biochem (2008) 3.32

Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res (2002) 3.25

Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance. Lancet Oncol (2001) 2.98

Homologous recombinational repair of DNA ensures mammalian chromosome stability. Mutat Res (2001) 2.95

The structure-specific endonuclease Mus81-Eme1 promotes conversion of interstrand DNA crosslinks into double-strands breaks. EMBO J (2006) 2.89

Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res (1999) 2.71

Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene (2009) 2.58

TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol (2012) 2.45

Identification and characterization of the human mus81-eme1 endonuclease. J Biol Chem (2003) 2.43

Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum Mol Genet (2001) 2.16

Measurement of cell proliferation by labeling of DNA with stable isotope-labeled glucose: studies in vitro, in animals, and in humans. Proc Natl Acad Sci U S A (1998) 2.05

Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin Cancer Res (2004) 2.04

Local UV-induced DNA damage in cell nuclei results in local transcription inhibition. EMBO Rep (2001) 1.99

UV-induced DNA damage, repair, mutations and oncogenic pathways in skin cancer. J Photochem Photobiol B (2001) 1.91

Targeting Stat3 abrogates EGFR inhibitor resistance in cancer. Clin Cancer Res (2012) 1.89

Signal transducer and activator of transcription-3: a molecular hub for signaling pathways in gliomas. Mol Cancer Res (2008) 1.80

Exploring the roles of Mus81-Eme1/Mms4 at perturbed replication forks. DNA Repair (Amst) (2007) 1.76

Eme1 is involved in DNA damage processing and maintenance of genomic stability in mammalian cells. EMBO J (2003) 1.68

Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer (2003) 1.67

Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br J Cancer (1996) 1.66

Wee1 controls genomic stability during replication by regulating the Mus81-Eme1 endonuclease. J Cell Biol (2011) 1.53

In situ visualization of ultraviolet-light-induced DNA damage repair in locally irradiated human fibroblasts. J Invest Dermatol (2001) 1.52

Structure-specific DNA endonuclease Mus81/Eme1 generates DNA damage caused by Chk1 inactivation. PLoS One (2011) 1.34

Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. Neuro Oncol (2010) 1.31

Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1alpha. Mol Cancer (2007) 1.27

Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patients. PLoS One (2011) 1.27

The nature of mutants induced by ionising radiation in cultured hamster cells. III. Molecular characterization of HPRT-deficient mutants induced by gamma-rays or alpha-particles showing that the majority have deletions of all or part of the hprt gene. Mutat Res (1986) 1.22

p53 modulates acquired resistance to EGFR inhibitors and radiation. Cancer Res (2011) 1.17

Cetuximab augments cytotoxicity with poly (adp-ribose) polymerase inhibition in head and neck cancer. PLoS One (2011) 1.03

The EGFR-STAT3 oncogenic pathway up-regulates the Eme1 endonuclease to reduce DNA damage after topoisomerase I inhibition. Cancer Res (2008) 1.02

STAT3 modulates the DNA damage response pathway. Int J Exp Pathol (2010) 1.00

Gefitinib resistance resulted from STAT3-mediated Akt activation in lung cancer cells. Oncotarget (2013) 0.91

Postreplication repair in ultraviolet-irradiated human fibroblasts: formation and repair of DNA double-strand breaks. Carcinogenesis (1986) 0.91

Curcumin induces stress response, neurite outgrowth and prevent NF-kappaB activation by inhibiting the proteasome function. Neurotox Res (2006) 0.91

Functional evidence for Eme1 as a marker of cisplatin resistance. Int J Cancer (2009) 0.90

Potential use of STAT3 inhibitors in targeted prostate cancer therapy: future prospects. Onco Targets Ther (2012) 0.90

Cetuximab and chemoradiation for rectal cancer--is the water getting muddy? Acta Oncol (2010) 0.87

Cetuximab induces mitochondrial translocalization of EGFRvIII, but not EGFR: involvement of mitochondria in tumor drug resistance? Tumour Biol (2011) 0.85

Intracytoplasmic epidermal growth factor receptor shows poor response to the cetuximab antitumor effect in irradiated non-small cell lung cancer cell lines. Lung Cancer (2012) 0.84

Combination of cetuximab with chemoradiation, trastuzumab or MAPK inhibitors: mechanisms of sensitisation of cervical cancer cells. Br J Cancer (2009) 0.83

A review of clinical trials of cetuximab combined with radiotherapy for non-small cell lung cancer. Radiat Oncol (2012) 0.81

Inhibition of poly(ADP-ribose) polymerase (PARP) and ataxia telangiectasia mutated (ATM) on the chemosensitivity of mantle cell lymphoma to agents that induce DNA strand breaks. Hematol Oncol (2011) 0.81

Effects of anti-EGFR antibody cetuximab on androgen-independent prostate cancer cells. Anticancer Res (2010) 0.78